TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 203-210

  Børresen Dale, Anne Lise ^a   Lothe, Ragnhild A ^a   Meling, Gunn I ^a   Hainaut, Pierre ^b   Rognum, Torleiv O ^a   Skovlund, Eva ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53; ZINC;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CHROMOSOME 17P; COLORECTAL CANCER; CONTROLLED STUDY; DIPLOIDY; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; RECTUM TUMOR; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BINDING SITES; COLORECTAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SURVIVAL RATE; ZINC;

EID: 0031929626     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. DeCosse, J. J., Tsioulias, G. J., and Jacobson, J. S. Colorectal cancer: detection, treatment, and rehabilitation. CA Cancer J. Clin., 44: 27-42, 1994.
2. Nathanson, S. D., Schultz, L., Tilley, B., and Kambouris, A. Carcinomas of the colon and rectum: a comparison of staging. Am. Surg., 52: 428-433, 1986.
3. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
4. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
5. Fearon, E. R., and Vogelstein, B. A. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
6. Hamelin, R., Laurent-Puig, P., Olschwang, S., Jego, N., Asselain, B., Remivikos, Y., Girodet, J., Salmon, R. J., and Thomas, G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology, 106: 42-48, 1994.
7. Goh, H-S., Yao, J., and Smith, D. R. p53 point mutation and survival in colorectal cancer patients. Cancer Res., 55: 5217-5221, 1995.
8. Smith, D. R., Ji, C-Y., and Goh, H-S. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br. J. Cancer, 74: 216-223, 1996.
9. Pricolo, V. E., Finkelstein, S. D., Wu, T-T., Keller, G., Bakker, A., Swalsky, P. A., and Bland, K. I. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am. J. Surg., 171: 41-46, 1996.
10. WAF1/Cip1 in colorectal carcinoma. Br. J. Cancer, 74: 165-171, 1996.
11. Dix, B., Robbins, P., Carrello, S., House, A., and Iacopetta, B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br. J. Cancer, 70: 585-590, 1994.
12. Bell, S. M., Scott, N., Cross, D., Sagar, P., Lewis, F. A., Blair, G. E., Taylor, G. R., Dixon, M. F., and Quirke, P. Prognostic value of p53 over-expression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology, 104: 57-64, 1993.
13. Mulder, J-W. R., Baas, I. O., Polak, M. M., Goodman, S. N., and Offerhaus, G. J. A. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br. J. Cancer, 71: 1257-1262, 1995.
14. Nathanson, S. D., Linden, M. D., Tender, P., Zarbo, R. J., Jacobson, G., and Nelson, L. S. Relationship among p53, stage and prognosis of large bowel cancer. Dis. Colon Rectum, 37: 527-534, 1994.
15. Scott, N., Sagar, P., Stewart, J. Blair, G. E., Dixon, H. F., and Quirke, P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br. J. Cancer, 63: 317-319, 1991.
16. Sun, X-F., Carstensen, J. M., Zhang, H., Stål, O., Wingren, S., Hatschek, T., and Nordenskjöld, B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet, 340: 1369-1373, 1992.
17. Martinez, J., Georgoff, I., Martinez, J., and Levine, A. J. Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev., 5: 151-159, 1991.
18. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis is induced by p53 dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
19. Lane, D. P. Cancer: a death in the life of p53. Nature (Lond.), 362: 786-787, 1993.
20. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
21. Shaw, P., Bovey, R., Tardy, S., Sahli, R., and Costa, J. Induction of apoptosis by wild-type p53 in human colon tumor derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
22. Bakalkin, G., Yakovleva, T., Selivanova, G., Magnusson, K. P., Szekely, L., Kiseleva, E., Klein, G., Terenius, L., and Wiman, K. G. P53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl. Acad. Sci. USA, 91: 413-417, 1994.
23. Wang, T. C., Zukerberg, L., Lees, E., Arnold, A., and Schmidt, E. V. Mammary hyperplasia and carcinoma in MMTV-CYCLIN D1 transgenic mice. Nature (Lond.), 369: 669-671, 1994.
24. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. P. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Washington DC), 265: 1582-1584, 1994.
25. Bond, J. A., Blaydes, J. P., Rowson, J., Haughton, M. F., Smith, J. R., Wynford-Thomas, D., and Wyllie, F. S. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res., 55: 2404-2409, 1995.
26. Shaulsky, G., Goldfinger, N., and Rotter, V. Alteration in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res., 51: 5232-5237, 1991.
27. Soussi, T., DeFromentel, C. C., and May, P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5: 945-952, 1990.
28. Cho, Y., Gorina, S., Jeffery, P. D., and Pavletich, N. P. Crystal structure of a TP53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Washington DC), 256: 346-355, 1994.
29. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the TP53 tumor suppressor transactivating domain. Science (Washington DC), 274: 948-953, 1996.
30. Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
31. Børresen, A-L., Andersen, T. I., Cornelis, R. S., Cornelisse, C. J., Eyfjord, J., Thorlacius, S., Borg, Å., Theillet, C., Scherneck, S., Hartman, S., Hovig, E., and Devilee, P. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domain. Genes Chromosomes Cancer, 14: 71-75, 1995.
32. Aas, T., Børresen, A-L., Geisler, S., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lønning, P. E. Specific TP53 mutations are associated with de novo resistance to doxorubicin therapy in breast cancer patients. Nat. Med., 2: 811-814, 1996.
33. Meling, G. I., Lothe, R. A., Børresen, A-L., Hauge, S., Graue, C., Clausen, O. P. F., and Rognum, T. O. Genetic alterations within the retinoblastoma locus in colorectal carcinomas: relation to DNA ploidy pattern studied by flow cytometric analysis. Br. J. Cancer, 64: 475-480, 1991.
34. Meling, G. I., Lothe, R. A., Børresen, A-L., Graue, C., Hauge, S., Clausen, O. P. F., and Rognum, T. O. The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic alterations on chromosome 17. Br. J. Cancer, 67: 88-92, 1993.
35. Lothe, R. A., Peltomäki, P., Meling, G. I., Aaltonen, L., Nyström-Lahti, M., Pylkkänen, L., Heimdal, K., Andersen, T. I., Møller, P., Rognum, T. O., Fosså, S. D., Haldorsen, T., Langmark, F., Brøgger, A., de la Chapelle, A., and Børresen, A-L. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res., 53: 5849-5852, 1993.
36. Børresen, A-L., Hovig, E., Smith-Sørensen, B., Malkin, D., Lystad, S., Andersen, T. I., Nesland, J. M., Isselbacher, K. J., and Friend, S. Constant denaturant gel electrophoresis (CDGE) as a rapid screening technique for p53 mutations. Proc. Natl. Acad. Sci. USA, 88: 8405-8409, 1991.
37. Andersen, T. I., and Børresen, A-L. Alteration of the TP53 gene as a potential prognostic marker in breast carcinomas: advantages of using CDGE in mutation detection. Diagn. Mol. Pathol., 4: 203-211, 1995.
38. Børresen, A-L. Constant denaturant gel electrophoresis (CDGE) in mutation screening. In: G. P. Pfeifer (ed.), Technologies for Detection of DNA Damage and Mutation, pp. 267-279. New York: Plenum Press, 1996.
39. Hainaut, P., Soussi, T., Shomer, B., Hollstein, M., Greenblatt, M., Hovig, E., Harris, C. C., and Montesano, R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res., 25: 151-157, 1997.
40. Carder, P. J., Cripps, K. J., Morris, R., Collins, S., White, S., Bird, C. C., and Wyllie, A. H. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br. J. Cancer, 71: 215-218, 1995.
41. Kahlenberg, M. S., Stoler, D. L., Basik, M., Petrelli, N. J., Rodriguez-Bigas, M., and Anderson, G. R. p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers. J. Natl. Cancer Inst., 88: 1665-1670, 1996.
42. + status and p53 mutation in colorectal cancer cell lines. Oncogene, 13: 2727-2730, 1996.
43. Preudhomme, C., Lepelley, P., Vachee, A., Soenen, V., Quesnel, B., Cosson, A., and Fenaux, P. Relation between p53 gene mutation and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia (Baltimore), 7: 1888-1889, 1993.
44. 1-S boundary after irradiation. Oncogene, 12: 875-882, 1996.
45. Iwamoto, K. S., Mizuno, T., Ito, T., Tsuyama, N., Kyoizumi, S., and Seyama, T. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival. Cancer Res., 56: 3862-3865, 1996.